180 related articles for article (PubMed ID: 32990903)
1. The EphA2 and cancer connection: potential for immune-based interventions.
London M; Gallo E
Mol Biol Rep; 2020 Oct; 47(10):8037-8048. PubMed ID: 32990903
[TBL] [Abstract][Full Text] [Related]
2. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors.
Noberini R; Koolpe M; Peddibhotla S; Dahl R; Su Y; Cosford ND; Roth GP; Pasquale EB
J Biol Chem; 2008 Oct; 283(43):29461-72. PubMed ID: 18728010
[TBL] [Abstract][Full Text] [Related]
3. Targeting EphA2 in cancer.
Xiao T; Xiao Y; Wang W; Tang YY; Xiao Z; Su M
J Hematol Oncol; 2020 Aug; 13(1):114. PubMed ID: 32811512
[TBL] [Abstract][Full Text] [Related]
4. PET-Guided Evaluation and Optimization of Internalized Antibody-Drug Conjugates Targeting Erythropoietin-Producing Hepatoma A2 Receptor.
Jacobson O; Li Q; Chen H; Niu G; Kiesewetter DO; Xu L; Cook K; Yang G; Dall'Acqua W; Tsui P; Peng L; Chen X
J Nucl Med; 2017 Nov; 58(11):1838-1844. PubMed ID: 28546337
[TBL] [Abstract][Full Text] [Related]
5. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.
Martini G; Cardone C; Vitiello PP; Belli V; Napolitano S; Troiani T; Ciardiello D; Della Corte CM; Morgillo F; Matrone N; Sforza V; Papaccio G; Desiderio V; Paul MC; Moreno-Viedma V; Normanno N; Rachiglio AM; Tirino V; Maiello E; Latiano TP; Rizzi D; Signoriello G; Sibilia M; Ciardiello F; Martinelli E
Mol Cancer Ther; 2019 Apr; 18(4):845-855. PubMed ID: 30824612
[TBL] [Abstract][Full Text] [Related]
6. EPH receptor A2 governs a feedback loop that activates Wnt/β-catenin signaling in gastric cancer.
Peng Q; Chen L; Wu W; Wang J; Zheng X; Chen Z; Jiang Q; Han J; Wei L; Wang L; Huang J; Ma J
Cell Death Dis; 2018 Nov; 9(12):1146. PubMed ID: 30451837
[TBL] [Abstract][Full Text] [Related]
7. Critical role of EphA3 in cancer and current state of EphA3 drug therapeutics.
London M; Gallo E
Mol Biol Rep; 2020 Jul; 47(7):5523-5533. PubMed ID: 32621117
[TBL] [Abstract][Full Text] [Related]
8. Elevated Expression of EPHA2 Is Associated With Poor Prognosis After Radical Prostatectomy in Prostate Cancer.
Kurose H; Ueda K; Kondo R; Ogasawara S; Kusano H; Sanada S; Naito Y; Nakiri M; Nishihara K; Kakuma T; Akiba J; Igawa T; Yano H
Anticancer Res; 2019 Nov; 39(11):6249-6257. PubMed ID: 31704854
[TBL] [Abstract][Full Text] [Related]
9. Cotargeting Ephrin Receptor Tyrosine Kinases A2 and A3 in Cancer Stem Cells Reduces Growth of Recurrent Glioblastoma.
Qazi MA; Vora P; Venugopal C; Adams J; Singh M; Hu A; Gorelik M; Subapanditha MK; Savage N; Yang J; Chokshi C; London M; Gont A; Bobrowski D; Grinshtein N; Brown KR; Murty NK; Nilvebrant J; Kaplan D; Moffat J; Sidhu S; Singh SK
Cancer Res; 2018 Sep; 78(17):5023-5037. PubMed ID: 29945963
[TBL] [Abstract][Full Text] [Related]
10. C1GALT1 is associated with poor survival and promotes soluble Ephrin A1-mediated cell migration through activation of EPHA2 in gastric cancer.
Lee PC; Chen ST; Kuo TC; Lin TC; Lin MC; Huang J; Hung JS; Hsu CL; Juan HF; Lee PH; Huang MC
Oncogene; 2020 Mar; 39(13):2724-2740. PubMed ID: 32005975
[TBL] [Abstract][Full Text] [Related]
11. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics.
Ireton RC; Chen J
Curr Cancer Drug Targets; 2005 May; 5(3):149-57. PubMed ID: 15892616
[TBL] [Abstract][Full Text] [Related]
12. Human dendritic cells express neuronal Eph receptor tyrosine kinases: role of EphA2 in regulating adhesion to fibronectin.
de Saint-Vis B; Bouchet C; Gautier G; Valladeau J; Caux C; Garrone P
Blood; 2003 Dec; 102(13):4431-40. PubMed ID: 12907451
[TBL] [Abstract][Full Text] [Related]
13. An ephrin mimetic peptide that selectively targets the EphA2 receptor.
Koolpe M; Dail M; Pasquale EB
J Biol Chem; 2002 Dec; 277(49):46974-9. PubMed ID: 12351647
[TBL] [Abstract][Full Text] [Related]
14. Cancer-associated fibroblasts promote gastric tumorigenesis through EphA2 activation in a ligand-independent manner.
Hong HN; Won YJ; Shim JH; Kim HJ; Han SH; Kim BS; Kim HS
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1649-1663. PubMed ID: 29948146
[TBL] [Abstract][Full Text] [Related]
15. A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers.
Gan HK; Parakh S; Lee FT; Tebbutt NC; Ameratunga M; Lee ST; O'Keefe GJ; Gong SJ; Vanrenen C; Caine J; Giovannetti M; Murone C; Scott FE; Guo N; Burvenich IJG; Paine C; Macri MJ; Kotsuma M; Senaldi G; Venhaus R; Scott AM
Invest New Drugs; 2022 Aug; 40(4):747-755. PubMed ID: 35404015
[TBL] [Abstract][Full Text] [Related]
16. Emerging strategies for EphA2 receptor targeting for cancer therapeutics.
Tandon M; Vemula SV; Mittal SK
Expert Opin Ther Targets; 2011 Jan; 15(1):31-51. PubMed ID: 21142802
[TBL] [Abstract][Full Text] [Related]
17. Exploring the potential of EphA2 receptor signaling pathway: a comprehensive review in cancer treatment.
Nehal M; Khatoon J; Akhtar S; Khan MKA
Mol Biol Rep; 2024 Feb; 51(1):337. PubMed ID: 38393520
[TBL] [Abstract][Full Text] [Related]
18. Optimization of stereospecific targeting technique for selective production of monoclonal antibodies against native ephrin type-A receptor 2.
Yamasaki Y; Miyamae C; Isozaki Y; Ichikawa K; Kaneko Y; Oda Y; Murayama T; Sakurai T; Tamai K; Tsumoto K; Tomita M
J Immunol Methods; 2020; 484-485():112813. PubMed ID: 32592774
[TBL] [Abstract][Full Text] [Related]
19. Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer.
Veiga RN; de Azevedo ALK; de Oliveira JC; Gradia DF
J Mol Med (Berl); 2024 Apr; 102(4):479-493. PubMed ID: 38393661
[TBL] [Abstract][Full Text] [Related]
20. The Role of the Eph Receptor Family in Tumorigenesis.
Anderton M; van der Meulen E; Blumenthal MJ; Schäfer G
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33430066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
